Composition of LDL particle discriminates between hypercholesterolaemic persons with and without symptoms of coronary heart disease

Annals of Clinical Biochemistry

Volumn 41, Issue 3, 2004, Pages 213-219

  Van Jaarsveld, Henretha ^a   Pool, Gertruida F ^a   Bester, Catharina J ^a  

^a UNIVERSITY OF THE FREE STATE   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; CHOLESTEROL; IRON; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CORONARY RISK; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; IRON BLOOD LEVEL; ISCHEMIC HEART DISEASE; LIPID OXIDATION; MALE; NORMAL HUMAN; OXIDATION REDUCTION POTENTIAL; PATIENT CODING; PRIORITY JOURNAL; RISK FACTOR; SYMPTOM;

ANTIOXIDANTS; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY DISEASE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; IRON; LIPID PEROXIDATION; MALE; MIDDLE AGED; NUTRITIONAL STATUS; OXIDATION-REDUCTION; RISK FACTORS; TRIGLYCERIDES;

EID: 2442575043     PISSN: 00045632     EISSN: None     Source Type: Journal    
DOI: 10.1258/000456304323019587     Document Type: Article

References (45)

1. Stary HC. Evolution and progression of atherosclerotic lesions in coronary arteries of children and young adults. Arteriosclerosis 1989; 9 (Suppl I): i19-i32
2. Strong JP, Malcolm GT, McMahan CA. Prevalence and extent of atherosclerosis in adolescents and young adults: Implications for prevention from the pathobiological determinants of atherosclerosis in youth study. JAMA 1999; 281: 727-35
3. Falk E, Fuster V. Angina pectoris and disease progression. Circulation 1995; 92: 2033-5
4. McNamara JR, Seman LJ, Schaefer EJ. The laboratory's role in identifying lipid and lipoprotein risk factors for CHD. Med Lab Observer 1999; 10: 24-33
5. Stamler J, Wentworth D, Neaton JD. Is the relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356 222 primary screens of the Multiple Risk Factor Intervention Trial (MRIT). JAMA 1986; 256: 2823-8
6. Yuan XM, Brunk UT. Iron and LDL oxidation in atherogenesis. Acta Pathol Microbiol Immunol Scand 1998; 106: 825-42
7. Kullo IJ, Gau GR, Taljik AJ. Novel risk factors for atherosclerosis. Mayo Clin Proc 2000; 75: 369-80
8. Sigal E, Laughton CW, Mulkins MA. Oxidation, lipoxigenase and athemgenesis. Ann NY Acad Sci 1994; 714: 211-24
9. Mosca L, Rubenfire M, Tarshis T, Tsai A, Pearson T. Clinical predictors of oxidized low-density lipoprotein in patients with coronary artery disease. Am J Cardiol 1997; 80: 825-30
10. Halevy DI, Thiery J, Nagel D, Arnold S, Erdmann E, Höflin B, et al. Increased oxidation of LDL in patients with coronary artery disease is independent from dietary vitamins E and C. Arterioscler Thromb Vasc Biol 1997; 17: 1432-7
11. Dogru-Abbasoglu S, Kanbagli O, Bulur H, Babalik E, Ozturk S, Aykac-Toker G, et al. Lipid peroxides and antioxidant status in serum of patients with angiographically defined coronary atherosclerosis. Clin Biochem 1999; 32: 671-2
12. Parks EJ, German JB, Davis PA, Frankel EN, Kappagoda CT, Rutledge JC, et al. Reduced oxidative susceptibility of LDL from patients participating in an intensive atherosclerosis treatment program. Am J Clin Nutr 1998; 68: 778-85
13. Reaven PD, Witzum JL. Oxidized low-density lipoprotein in atherogenesis: Role of dietary modification. Annu Rev Nutr 1996; 16: 51-71
14. Rice-Evans C, Leake D, Diplock AT. Practical approaches to low density lipoprotein oxidation: Why's, wherefores and pitfalls. Free Rad Res 1996; 25: 285-311
15. Habernicht AJ, Janssen-Timmen U, Ziegler R, Schnettler G. Lipopmteins and their functions. Clin Invest 1994; 72: 639-52
16. Esterbauer H, Ramos P. Chemistry and pathophysiology of oxidation of LDL. Rev Physiol Biochem Pharmacol 1996; 127: 31-64
17. Salonen JT, Nyyssönen K, Korpela H, Tuomilehto J, Seppänen R, Salonen R. High stored iron levels are associated with excess risk of myocardial infarction in Eastern Finnish men. Circulation 1992; 86: 803-11
18. Dabbagh AJ, Mannion T, Lynch SM, Frei B. The effect of iron overload on rat plasma and liver oxidant status in vivo. Biochem J 1994; 300: 799-803
19. Porreca E, Ucchino S, Di Febbo C, Di Bartolomeo N, Angelucci D, Napolitano AM, et al. Antiproliferative effect of desferrioxamine on vascular smooth muscle cells in vitro and in vivo. Arterioscler Thromb 1994; 14: 299-304
20. Esterbauer H, Striegl H, Puhl H, Rotheneder M. Continuous monitoring of in vitro oxidation of human low-density lipoprotein. Free Rad Res Commun 1989; 6: 67-75
21. Van Jaarsveld H, Kuyl JM, Strydom MS, Alberts DW. Chronic cigarette smoke exposure of rats results in significant changes in antoxidants in organs and plasma: effect of antoxidants in myocardial ischemia and reperfusion. Res Commun Mol Pathol Pharmacol 1994; 86: 273-85
22. Jiang ZY, Hunt JV, Wolff SP. Ferrous iron oxidation in the presence of xylonol orange for detection of lipid hydroperoxide in low-density lipoprotein. Annal Biochem 1992; 202: 384-9
23. Fairbanks VF, Klee GG. Biochemical aspects of hematology - Iron metabolism. In: CA Burtis, ER Ashwood WB, eds. Tietz Textbook of Clinical Chemistry 3rd edn. Pennsylvania: Saunders, 2000: 1698-710
24. Kirchner RE, Fantini GA. Role of iron and oxygen derived free radicals in ischemia/reperfusion injury. J Am Coll Surg 1994; 179: 103-17
25. Gey KF, Brubacher GB, Stahlin HB. Plasma levels of antioxidant vitamins in relation to ischaemic disease and cancer. Am J Clin Nutr 1987; 45: 1368-77
26. Kontush A, Spranger T, Reich A, Baum K, Belsiegel U. Lipophilic antioxidants in blood plasma as markers of atherosclerosis: The role of α-carotene and γ-tocopherol. Atherosclerosis 1999; 144: 117-22
27. Vogel RA. Cholesterol lowering and endothelial function. Am J Med 1999; 107: 479-87
28. Heinecke JW. Oxidants and antioxidants in the pathogenesis of atherosclerosis: Implications for the oxidized low density lipoprotein hypothesis. Atherosclerosis 1998; 141: 1-15
29. Tribble DL. Antioxidant consumption and risk of coronary heart disease: Emphasis on vitamin C, vitamin E and β-carotene. Circulation 1999; 99: 591-5
30. Parthasarathy S, Santanam N, Ramachandran S, Meilhac O. Oxidants and antioxidants in atherogenesis: An appraisal. J Lipid Res 1999; 40: 2143-57
31. Ferns G, Williams J, Forster L, Tull S, Starkey B, Gershlick A. Cholesterol standardized plasma vitamin E levels are reduced in patients with severe angina pectoris. Int J Exp Pathol 2000; 81: 57-62
32. Meraji S, Abuja PM, Hayn M, Kostner GM, Morris R, Oraii S, et al. Relationship between classic risk factors, plasma antioxidants and indicators of oxidant stress in angina pectoris (AP) in Tehra. Atherosclerosis 2000; 150: 403-12
33. Leonhardt W, Hanefeld M, Scaper F. Diminished susceptibility to in vitro oxidation of low-density lipoprotein in hypercholesterolaemia: Key role of alpha-tocopherol content. Atherosclerosis 1999; 144: 103-7
34. Pentiäinen MO, Öömi K, Ala-Korpela M, Kovanen PT. Modified LDL-trigger of atherosclerosis and inflammation in arterial intima. J Intern Med 2000; 247: 359-70
35. Reaven P, Parthasarathy S, Grasse BJ, Miller E, Steinberg D, Witztum JL. Effects of oleate-rich and linoleate-rich diets on the susceptibility of low density lipoprotein to oxidative modification in hypercholesterolemic subjects. J Clin Invest 1993; 91: 668-76
36. Perugini C, Bagnati M, Cau C, Bordone R, Paffoni P, Re R, et al. Distribution of lipid-soluble antioxidants in lipoproteins from healthy subjects. Pharmacol Res 2000; 41: 67-74
37. Goulinet S, Chapman MJ. Plasma LDL and HDL sub-species are heterogenous in particular contents of tocopherols and oxygenated and hydrocarbon carotenoids. Relevance to oxidative resistance and atherogenicity. Arterioscler Throm Vasc Biol 1997; 17: 786-96
38. Diaz MN, Frei B, Vita JA, Keaney JF. Antioxidants and atherosclerotic heart disease. N Engl J Med 1997; 337: 408-16
39. Meyers DG, Mololey PA. The antioxidant vitamins: Impact on atherosclerosis. Pharmacotherapy 1993; 13: 574-82
40. Zapolska-Downar D, Zapolski-Downar A, Markiewski M, Ciechanowicz A, Kaczmarczyk M, Naruszewicz M. Selective inhibition by alpha-tocopherol of vascular cell adhesion molecule-1 expression in human vascular endothelial cells. Biochim Biophys Res Commun 2000; 274: 609-15
41. Ozer NK, Azzi A. Effect of vitamin E on the development of atherosclerosis. Toxicology 2000; 148: 179-85
42. Ferns GA, Forster LA, Williams JC, Tull SP, Verma PK, Starkey B, et al. Effect of vitamin E supplementation on circulating cell adhesion molecules pre- and post-coronary angioplasty. Ann Clin Biochem 2000; 37: 649-54
43. Halliwell B. Drug antioxidant effects. A basis for drug selection. Drugs 1991; 42: 569-605
44. Asmis R, Jelk J. Vitamin E supplementation of human macrophages prevents neither foam cell formation nor increased susceptibility of foam cells to lysis by oxidized LDL. Arterioscler Thromb Vasc Biol 2000; 20: 2078-89
45. Simons LA, Von Koningsmark M, Simons J, Stocker R, Celermajer DS. Vitamin E ingestion does not improve arterial endothelial dysfunction in older adults. Atherosclerosis 1999; 143: 193-9